6 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaSchizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophreniaActive, not recruitingPhase 32026-10-05NCT06894212
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Alzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 32026-09-28NCT06937229
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderMania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorderRecruitingPhase 32026-09-22NCT06951698
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 32026-09-16NCT07011732
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)Mania, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorderRecruitingPhase 32026-09-14NCT06929273
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaSchizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophreniaRecruitingPhase 32026-07-27NCT06882785